H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Regulus Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Regulus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target
Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Oppenheimer Initiates Regulus Therapeutics at Outperform With $7 Price Target
Oppenheimer Initiates Regulus Therapeutics(RGLS.US) With Buy Rating, Announces Target Price $7
Regulus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target
Buy Rating Affirmed for Regulus Therapeutics Amid Positive RGLS8429 Study Results
HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $10
Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
Jones Trading Initiates Coverage On Regulus Therapeutics With Buy Rating, Announces Price Target of $8
Regulus Therapeutics Analyst Ratings
Buy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429
HC Wainwright & Co. : Reiterated Regulus Therapeutics (RGLS.US) rating, adjusted from buy to buy rating, target price of $9.00.